Characteristics and Costs of NASH Advanced Fibrosis and Cirrhosis in Patients with and without Diabetes Mellitus (DM): Results of a US Real-World Cohort Study

被引:0
|
作者
Sanyal, Arun J. [1 ]
Bengtson, Lindsay [2 ]
Shreay, Sanatan [3 ]
Kim, W. Ray [4 ]
机构
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Optum, Eden Prairie, MN USA
[3] Gilead Sci, HEOR, Foster City, CA USA
[4] Stanford Univ, Palo Alto, CA 94304 USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
2210
引用
收藏
页码:1168A / 1169A
页数:2
相关论文
共 50 条
  • [31] Comorbidity severity scores and cardiovascular comorbidities in patients with non-alcoholic steatohepatitis (NASH), with and without cirrhosis, in a real-world setting
    Lazarus, Jeffrey
    Chandramouli, Abhishek Shankar
    Mangla, Kamal Kant
    Younossi, Zobair
    JOURNAL OF HEPATOLOGY, 2022, 77 : S148 - S149
  • [32] REAL-WORLD INCIDENCE OF HYPOGLYCEMIA AND ASSOCIATED COSTS AMONG INSULIN GLARGINE-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Xie, L.
    Wei, W.
    Pan, C.
    Baser, O.
    VALUE IN HEALTH, 2012, 15 (07) : A493 - A493
  • [33] Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis
    Maan, Raoel
    Zaim, Remziye
    van der Meer, Adriaan J.
    Feld, Jordan J.
    Wedemeyer, Heiner
    Dufour, Jean-Francois
    Lammert, Frank
    Manns, Michael P.
    Zeuzem, Stefan
    Hansen, Bettina E.
    Janssen, Harry L. A.
    Veldt, Bart J.
    de Knegt, Robert J.
    Uyl-de Groot, Carin A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (11) : 1851 - 1859
  • [34] REAL-WORLD MEDICAL COSTS OF ANTIVIRAL THERAPY AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS
    Mann, R.
    Zaim, R.
    van der Meer, A.
    Feld, J.
    Wedemeyer, H.
    Dufour, J.
    Lammert, F.
    Manns, M.
    Zeuzem, S.
    Hansen, B.
    Janssen, H.
    Veldt, B.
    de Knegt, R.
    Uyo-de Groot, C.
    VALUE IN HEALTH, 2015, 18 (07) : A624 - A624
  • [35] Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer
    Veljovich, Dan Steven
    Penson, Richard T.
    Birrer, Michael J.
    Luo, Linlin
    Pyrih, Nick
    Pack, Simon
    Iu, Crystal
    Hada, Manila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Real-World Treatment for Diabetic Nephropathy (DN) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Chaudhari, Paresh
    Zhou, Zhou
    Yang, Hongbo
    Zhao, Jing
    Wu, Eric
    Seifeldin, Raafat
    DIABETES, 2016, 65 : A603 - A603
  • [37] Epidemiological characteristics of patients with pancreatic cancer with and without diabetes mellitus: A retrospective cohort study
    Eichinger, Sarah Elizabeth
    Dominguez, Alejandro Nieto
    Rivera, Daniel Guifarro
    Turk, Ekrem
    Pan, Chun-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 705 - 705
  • [38] Optyx study: Clinical characteristics and preferences for initiating relugolix in a cohort of US patients in real-world care settings.
    Spratt, Daniel Eidelberg
    McKay, Rana R.
    Ross, Ashley
    Lowentritt, Benjamin H.
    Flanders, Scott C.
    Zhong, Yi
    Hong, Agnes
    Ryan, Michael
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [39] Insulin use and gout risk among patients with type 2 diabetes mellitus: a real-world cohort study in Shanghai, China
    Jiying Qi
    Ping He
    Huayan Yao
    Wen Sun
    Ping Lu
    Xiaohui Qi
    Zizheng Zhang
    Renjie Jing
    Bin Cui
    Dongmei Liu
    Guang Ning
    Clinical Rheumatology, 2023, 42 : 3067 - 3073
  • [40] The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study
    Ose, Dominik J.
    Adediran, Emmanuel
    Mark, Bayarmaa
    Ocier, Krista
    Dunson, William A.
    Turner, Cindy
    Taylor, Belinda
    Svoboda, Kim
    Post, Andrew R.
    Leiser, Jennifer
    Colman, Howard
    Ulrich, Cornelia M.
    Hashibe, Mia
    CANCER MEDICINE, 2024, 13 (20):